Pfizer Inc. is aiming to bring its next-generation pneumococcal vaccine Prevnar 20 into the pediatric market – the larger market opportunity versus adults – so that it can be used in the same patients as the company's blockbuster Prevnar 13 and Merck & Co., Inc.'s newer 15-valent conjugate vaccine Vaxneuvance.
A Phase III clinical trial comparing the immunogenicity of the 20-valent pneumococcal conjugate vaccine candidate (20vPnC) to Prevnar 13 in infants at 2, 4, 6 and 12-15 months of age met the primary endpoint after four doses for all 20 serotypes, but
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?